{"id":"W2910867209","doi":"10.1001/jama.2018.20588","title":"Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis","year":2019,"lang":"en","type":"article","venue":"JAMA","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Notre-Dame; Université de Montréal","funders":"National Health and Medical Research Council; Debreceni Egyetem; Dokuz Eylül Üniversitesi; Università degli Studi di Firenze; Multiple Sclerosis Society; York University; Wellcome Trust; American University of Beirut; Jewish General Hospital; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Sanofi Genzyme; University of Melbourne; Medical Research Council; Biogen; NYU Langone Medical Center; NIHR Cambridge Biomedical Research Centre; Sanofi","keywords":"Medicine; Fingolimod; Glatiramer acetate; Natalizumab; Multiple sclerosis; Internal medicine; Hazard ratio; Alemtuzumab; Surgery; Disease; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002344854,0.0001297899,0.0002937679,0.0001181563,0.00006322355,0.0000284318,0.00008117313,0.00007116512,0.0005217342],"category_scores_gemma":[0.0003932557,0.0000920669,0.00007445252,0.0001777273,0.00004197685,0.0001657672,0.00008333932,0.0001980024,0.000109105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001584109,"about_ca_system_score_gemma":0.0001113781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004078095,"about_ca_topic_score_gemma":0.000006542627,"domain_scores_codex":[0.998576,0.00007079146,0.0001836291,0.0002564689,0.0006307753,0.0002822673],"domain_scores_gemma":[0.9987822,0.000238009,0.0001278245,0.0002365532,0.000434268,0.0001811614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004212237,0.0002022223,0.9220234,0.0002205368,0.0002860173,0.00001034475,0.0009973431,0.0000117765,0.04070013,0.000001749172,0.003418581,0.02791564],"study_design_scores_gemma":[0.009357638,0.0006450487,0.9515753,0.0004675147,0.00002776039,6.145518e-7,0.0002253075,0.0003408798,0.03477708,0.000001840023,0.002469092,0.0001119397],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994274,0.0001764341,0.000009005594,0.003325747,0.00008219838,0.001252462,0.00006253259,0.00003996122,0.0007776702],"genre_scores_gemma":[0.9979154,0.0001177357,0.0004689519,0.0006637745,0.0001385627,0.00007829122,0.00003771199,0.00002320581,0.0005562949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02955187,"threshold_uncertainty_score":0.5712623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0467230660719371,"score_gpt":0.3189398855219823,"score_spread":0.2722168194500452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}